Literature DB >> 7049585

Double-blind comparison of meptazinol (200 mg) and dextropropoxyphene/paracetamol in a multi-centre, general practice setting.

R K Price, A N Latham.   

Abstract

A multi-centre, double-blind, double-dummy trial was carried out in general practice to compare the effectiveness and tolerance of oral meptazinol with dextropropoxyphene/paracetamol in patients with acute or chronic painful conditions. Patients received doses of 400 mg meptazinol or 65 mg dextropropoxyphene plus 650 mg paracetamol every 3 to 6 hours as required up to a maximum of 4 doses per day over a period of 14 days. No significant difference in analgesic efficacy, as assessed by the patients on a visual analogue pain rating scale, was found between the two treatments. The results are discussed in terms of the benefit/risk ration of polypharmic and single compound drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049585     DOI: 10.1185/03007998209109758

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Pharmacokinetics of meptazinol after parenteral administration in the elderly.

Authors:  G R Murray; R A Franklin; D F Graham; R R Lewis; M E Bolland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Meptazinol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  B Holmes; A Ward
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

3.  The systemic availability of meptazinol in man after oral and rectal doses.

Authors:  G R Murray; O Petitjean; R A Franklin; D F Graham; J H Trouvin; C Jacquot
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Pharmacokinetics of meptazinol after single and multiple oral administration to elderly patients.

Authors:  H M Norbury; R A Franklin; D F Graham; B Sinha
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.